



## Supplement

# Effects of simvastatin on lipid metabolism in wild type mice and mice with muscle PGC-1 $\alpha$ overexpression

Miljenko V. Panajatovic <sup>1,2</sup>, Francois Singh <sup>1</sup>, Stephan Krähenbühl <sup>1</sup>, and Jamal Bouitbir <sup>3,\*</sup>

<sup>1</sup> Division of Clinical Pharmacology & Toxicology, University Hospital of Basel, Switzerland  
[m.panajatovic@unibas.ch](mailto:m.panajatovic@unibas.ch) (M.V.P.); [fzsingh@dundee.ac.uk](mailto:fzsingh@dundee.ac.uk) (F.S);  
[stephan.kraehenbuehle@unibas.ch](mailto:stephan.kraehenbuehle@unibas.ch) (S.K.)

<sup>2</sup> Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Switzerland

<sup>3</sup> Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Switzerland; [jamal.bouitbir@unibas.ch](mailto:jamal.bouitbir@unibas.ch) (J.B.)

\* Correspondence: [jamal.bouitbir@unibas.ch](mailto:jamal.bouitbir@unibas.ch); Tel.: +41 61 207 6290

**Citation:** Panajatovic, M.V.; Singh, F.; Krähenbühl, S.; Bouitbir, J. Effects of Simvastatin on Lipid Metabolism in Wild-Type Mice and Mice with Muscle PGC-1 $\alpha$  Overexpression. *Int. J. Mol. Sci.* **2021**, *22*, 4950.  
<https://doi.org/10.3390/ijms22094950>

Academic Editor: Gaetano Villani

Received: 14 March 2021

Accepted: 1 May 2021

Published: 7 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors.

Submitted for possible open access

publication under the terms and


conditions of the Creative Commons

Attribution (CC BY) license

(<http://creativecommons.org/licenses/by/4.0/>).




**Suppl. Fig. 1**



**Supplementary figure 1.** *Physiological characteristics over the course of the treatment.* To monitor the welfare and possible differences between groups, body weight (A), food intake (B), and water intake (C) were followed over the course of 21 days of treatment. Data are presented as mean  $\pm$  SEM of 10 animals per group. Symbols on the graphs are as follows: Ctl, control; OE, PGC-1 $\alpha$  overexpressing mice; Simv, simvastatin; WT, wild type




Suppl. Fig. 2



**Supplementary figure 2.** Expression of PGC-1 $\alpha$  mRNA in skeletal muscle. Switch from glycolytic to oxidative metabolism is regulated by PGC-1 $\alpha$ , which leads to increase in mitochondria number, and increase in fatty acid uptake and metabolism. We assessed the muscle mRNA expression of peroxisome proliferator activated receptor gamma coactivator 1 alpha (*Ppargc1a*). Data are presented as mean  $\pm$  SEM of 8 animals per group. After two-way ANOVA analysis, the treatment factor, the animal model factor, and the interaction between treatment and animal model was significant. Symbols on the graphs are as follows: \*  $p < .05$  simvastatin-treated vs. respective water-treated (control) mice; and #  $P < .05$  PGC-1 $\alpha$  OE vs. WT mice of the same treatment group (water or simvastatin). Ctl, control; OE, PGC-1 $\alpha$  overexpressing mice; Simv, simvastatin; WT, wild type



Suppl. Fig. 3



**Supplementary figure 3.** *mRNA expression of lipoprotein lipase (Lpl) in skeletal muscle.* Lipoprotein lipase hydrolyzes triglycerides from circulating low or very low-density lipoproteins. Data are presented as mean  $\pm$  SEM of 8 animals per group. After two-way ANOVA analysis, the animal model factor was significant. Symbols on the graphs are as follows: \* $P < .05$  between simvastatin-treated and respective control mice; and #  $P < .05$  PGC-1 $\alpha$  OE vs. WT mice of the same treatment group (water or simvastatin). Ctl, control; OE, PGC-1 $\alpha$  overexpressing mice; Simv, simvastatin; WT, wild type